Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2
Journal of Clinical Immunology · 2023
DOI: 10.1007/s10875-023-01445-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2023. Verfasst von Gaofeng Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Interferon Type I. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, HORIZON EUROPE European Research Council.
Abstract (Originalsprache)
Purpose
STAT2 is both an effector and negative regulator of type I interferon (IFN-I) signalling. We describe the characterization of a novel homozygous missense STAT2 substitution in a patient with a type I interferonopathy.
Methods
Whole-genome sequencing (WGS) was used to identify the genetic basis of disease in a patient with features of enhanced IFN-I signalling. After stable lentiviral reconstitution of STAT2-null human fibrosarcoma U6A cells with STAT2 wild type or p.(A219V), we performed quantitative polymerase chain reaction, western blotting, immunofluorescence, and co-immunoprecipitation to functionally characterize the p.(A219V) variant.
Results
WGS identified a rare homozygous single nucleotide transition in STAT2 (c.656C > T), resulting in a p.(A219V) substitution, in a patient displaying developmental delay, intracranial calcification, and up-regulation of interferon-stimulated gene (ISG) expression in blood. In vitro studies revealed that the STAT2 p.(A219V) variant retained the ability to transduce an IFN-I stimulus. Notably, STAT2 p.(A219V) failed to support receptor desensitization, resulting in sustained STAT2 phosphorylation and ISG up-regulation. Mechanistically, STAT2 p.(A219V) showed defective binding to ubiquitin specific protease 18 (USP18), providing a possible explanation for the chronic IFN-I pathway activation seen in the patient.
Conclusion
Our data indicate an impaired negative regulatory role of STAT2 p.(A219V) in IFN-I signalling and that mutations in STAT2 resulting in a type I interferonopathy state are not limited to the previously reported R148 residue. Indeed, structural modelling highlights at least 3 further residues critical to mediating a STAT2-USP18 interaction, in which mutations might be expected to result in defective negative feedback regulation of IFN-I signalling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
- Cytokine Signalling Unit, Institut Pasteur, Paris, France.
- Institut Imagine, Paris, France.
- Division of Evolution, Infection and Genomics, The University of Manchester, Manchester, UK.
- Centre National de Recherche en Génomique Humaine (CNRGH), Université Paris-Saclay, CEA, Evry, France.
- Institut de Génétique Médicale d'Alsace, Strasbourg, France.
Förderung
- Medical Research Council
- HORIZON EUROPE European Research Council
Zitieren
APA
Zhu, G., Badonyi, M., Franklin, L., Seabra, L., Rice, G. I., Anne-Boland-Auge, Deleuze, J. F., El-Chehadeh, S., Anheim, M., de Saint-Martin, A., Pellegrini, S., Marsh, J. A., Crow, Y. J., & El-Daher, M. T. (2023). Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-023-01445-3
Vancouver
Zhu G, Badonyi M, Franklin L, Seabra L, Rice GI, Anne-Boland-Auge, et al. Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2. Journal of Clinical Immunology. 2023. doi:10.1007/s10875-023-01445-3
BibTeX
@article{Zhu2023,
author = {Zhu, Gaofeng and Badonyi, Mihaly and Franklin, Lina and Seabra, Luis and Rice, Gillian I and Anne-Boland-Auge and Deleuze, Jean-François and El-Chehadeh, Salima and Anheim, Mathieu and de Saint-Martin, Anne and Pellegrini, Sandra and Marsh, Joseph A and Crow, Yanick J and El-Daher, Marie-Therese},
title = {Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2},
journal = {Journal of Clinical Immunology},
year = {2023},
doi = {10.1007/s10875-023-01445-3}
}
EUVIMED